MicroGeneSys' VaxSyn HIV therapeutic vaccine

Executive Summary

The "disapproval notification period" for the Phase III trial of the gp160 vaccine has been extended for an additional six months following President Clinton's signing of the FY 1994 Defense Department appropriations bill on Nov. 11. The language agreed to in the funding bill's conference report, which passed both chambers Nov. 10, implements an amendment offered by Rep. Waxman (D-Calif.) Sept. 30 ("The Pink Sheet" Oct. 11, T&G-9). MicroGeneSys says Nov. 12 that it is "concerned that the recent congressional action will likely delay Phase III trials of gp160 in the United States.".